Researchers believe that combining navitoclax with ruxolitinib will help those with myelofibrosis. During this trial half the folks have navitoclax and ruxolitinib. The opposite fifty percent have ruxolitinib and a dummy drug (placebo ). This trial was sponsored by Abbott Laboratories and Genentech. M06-814 was the first in human protocol https://ax-1583611987.blogsmine.com/26607438/detailed-notes-on-lxh254